Every processed story in chronological order, with the newest coverage first. Filter by tag, source, or score to drill in.
Radical's closed-loop SDL demonstrates that pairing an AI scientist with automated robotics can compress the materials discovery timeline by nearly an order of magnitude compared to a major government-industry program, with ten commercially promising novel materials already in development from a single campaign.
Practitioners building AI tools for biotech should note that TARIO-2's ability to extract rich tumor biology from a universally available assay (H&E) — and GSK's willingness to license it as a platform — signals a viable commercial path for AI software in drug development beyond the typical pivot to in-house drug discovery.